Lendormin

Brotizolam, the active ingredient in Lendormin, is a benzodiazepine presented as an oral dosage form for oral use. It is prescribed to manage insomnia by promoting sleep onset and maintenance. GNH USA supplies Lendormin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Brotizolam is a benzodiazepine that acts on the central nervous system to facilitate sleep. - Sleep onset insomnia: reduces the time required to fall asleep. - Sleep maintenance insomnia: decreases the number of nocturnal awakenings. - Transient insomnia: provides short‑term relief of occasional sleep difficulty.

Brotizolam may cause a range of adverse reactions.

Common Side Effects: - Drowsiness: feeling unusually sleepy during the day. - Dizziness: sensation of light‑headedness or unsteadiness. - Fatigue: persistent lack of energy. - Headache: mild to moderate cranial pain. - Dry mouth: reduced salivation causing throat discomfort. - Amnesia: difficulty recalling events after taking the medication.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing, especially with other depressants. - Dependence or withdrawal syndrome: difficulty stopping the drug after prolonged use. - Paradoxical reactions: agitation, aggression, or increased anxiety. - Severe skin reactions: rash, Stevens‑Johnson syndrome. - Suicidal thoughts: emergence of depressive or self‑harm ideation.

Brotizolam requires careful use to minimise risks. - Avoid use in severe respiratory insufficiency: risk of further breathing compromise. - Caution in elderly patients: increased fall and fracture risk due to sedation. - Do not combine with alcohol or other CNS depressants: additive sedation may occur. - Limit duration of therapy: recommended for short‑term use to reduce dependence. - Pregnancy and lactation: consult a healthcare professional before use. - Store at ambient temperature: keep in the original pack, protect from moisture.

Brotizolam can interact with several drug classes, altering its safety profile.

Major Interactions (Avoid): - Other CNS depressants (e.g., opioids, barbiturates): may cause profound sedation or respiratory depression. - Alcohol: additive central nervous system depression. - Potent CYP3A4 inhibitors (e.g., ketoconazole): can increase brotizolam plasma concentrations.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin): may modestly raise drug levels. - CYP3A4 inducers (e.g., rifampicin): may reduce therapeutic effect. - Certain antidepressants (e.g., SSRIs): can enhance sedative effects.